Annals of Allergy Asthma & Immunology最新文献

{"title":"From the pages of AllergyWatch","authors":"Stanley M. Fineman MD , Shyam R. Joshi MD , Timothy Chow MD , Samantha M. Knox MD","doi":"10.1016/j.anai.2026.01.004","DOIUrl":"10.1016/j.anai.2026.01.004","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 616-617"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole food-item intake status in adult food protein-induced enterocolitis syndrome (FPIES)","authors":"Sho Watanabe MD, PhD , Kiwako Yamamoto-Hanada MD, PhD , Tatsuki Fukuie MD, PhD , Yukihiro Ohya MD, PhD , Ichiro Nomura MD, PhD","doi":"10.1016/j.anai.2026.02.016","DOIUrl":"10.1016/j.anai.2026.02.016","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 607-610"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities","authors":"Ellen R. Sher MD ,&nbsp;Alexandra Golant MD ,&nbsp;Marjolein de Bruin-Weller MD, PhD ,&nbsp;Jose-Manuel Carrascosa MD, PhD ,&nbsp;Vinay Mehta MD ,&nbsp;Thomas Bieber MD, MDRA ,&nbsp;Zach Dawson PhD ,&nbsp;Amber Reck Atwater MD ,&nbsp;Jinglin Zhong MS ,&nbsp;Lidia Rodriguez Calleja PhD ,&nbsp;Mark Boguniewicz MD","doi":"10.1016/j.anai.2025.12.017","DOIUrl":"10.1016/j.anai.2025.12.017","url":null,"abstract":"<div><h3>Background</h3><div>Atopic comorbidities are common in patients with atopic dermatitis (AD) and increase disease burden. Lebrikizumab monotherapy demonstrated efficacy and safety through 52 weeks in patients with moderate-to-severe AD in phase 3 trials (ADvocate1 [NCT04146363]; ADvocate2 [NCT04178967]).</div></div><div><h3>Objective</h3><div>To evaluate the impact of atopic comorbidities on lebrikizumab efficacy and response maintenance in patients with AD using pooled data from ADvocate1 and ADvocate2.</div></div><div><h3>Methods</h3><div>At the end of the 16-week induction period, patients responding to lebrikizumab treatment every 2 weeks were re-randomized to receive lebrikizumab every 2 weeks, every 4 weeks, or placebo (withdrawal) for 36 additional weeks. Eczema Area and Severity Index (EASI) with at least 75% or 90% improvement (EASI 75; EASI 90), Pruritus Numeric Rating Scale with at least 4-point improvement, Investigator’s Global Assessment 0 or 1, and Asthma Control Questionnaire-5 results were assessed at weeks 16 and 52. Dermatology Quality of Life Index and sleep loss due to pruritus were assessed at week 16.</div></div><div><h3>Results</h3><div>Of 851 patients, 614 (72.2%) reported at least 1 atopic comorbidity. At week 16, significantly more lebrikizumab- vs placebo-treated patients achieved EASI 75, Pruritus Numeric Rating Scale with at least 4-point improvement, Investigator’s Global Assessment 0 or 1, and EASI 90 (<em>P</em> &lt; .001), regardless of atopic comorbidities. Results were similar for Dermatology Quality of Life Index and sleep loss. Most lebrikizumab responders at week 16, both with and without atopic comorbidities, maintained skin and pruritus response to week 52; Asthma Control Questionnaire-5 scores remained stable.</div></div><div><h3>Conclusion</h3><div>The presence or absence of atopic comorbidities did not affect the efficacy of lebrikizumab at weeks 16 and 52 in patients with moderate-to-severe AD.</div></div><div><h3>Trial Registration</h3><div>ClinicalTrials.gov Identifiers: NCT04146363 and NCT04178967 (<span><span>https://clinicaltrials.gov/study/NCT04146363</span><svg><path></path></svg></span>; <span><span>https://www.clinicaltrials.gov/study/NCT04178967</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 565-571"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145821940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pin the tail on the inhaler","authors":"Erin L. Reigh MD, MS","doi":"10.1016/j.anai.2025.11.020","DOIUrl":"10.1016/j.anai.2025.11.020","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 529-530"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S1081-1206(26)00141-9","DOIUrl":"10.1016/S1081-1206(26)00141-9","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Page A1"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Skin as the target for allergy prevention and treatment’ [Annals of Allergy, Asthma & Immunology, Volume 133, Issue 2 (2024) 133–143]","authors":"Andreina Marques-Mejias MD, PhD ,&nbsp;Irene Bartha MD ,&nbsp;Christina E. Ciaccio MD ,&nbsp;R. Sharon Chinthrajah MD ,&nbsp;Susan Chan MBBS, MD ,&nbsp;Gurjit K. Khurana Hershey MD, PhD ,&nbsp;Jessica W. Hui-Beckman MD ,&nbsp;Laurie Kost MS in Epidemiology, MS in Biological Sciences ,&nbsp;Gideon Lack MD, MBBCh ,&nbsp;Janice A. Layhadi PhD ,&nbsp;Donald Y.M. Leung MD, PhD ,&nbsp;Hannah F. Marshall MBChB ,&nbsp;Kari C. Nadeau MD, PhD ,&nbsp;Suzana Radulovic MD ,&nbsp;Reena Rajcoomar RN, BScN, HBSc ,&nbsp;Mohamed H. Shamji PhD ,&nbsp;Sayantani Sindher MD ,&nbsp;Helen A. Brough MA (Hons), MSc, PhD, MBBS","doi":"10.1016/j.anai.2026.03.010","DOIUrl":"10.1016/j.anai.2026.03.010","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Page 618"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IgE testing in risk stratification of common variable immunodeficiency","authors":"Caroline Schissel BS ,&nbsp;Jocelyn R. Farmer MD, PhD","doi":"10.1016/j.anai.2026.01.018","DOIUrl":"10.1016/j.anai.2026.01.018","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 506-507"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing patient perspectives and evidence in food protein-induced enterocolitis syndrome (FPIES)","authors":"Marcus Shaker MD, MS ,&nbsp;Aikaterini Anagnostou MD, PhD ,&nbsp;Elissa M. Abrams MD, MPH ,&nbsp;Matthew Greenhawt MD, MBA, MSc","doi":"10.1016/j.anai.2026.01.014","DOIUrl":"10.1016/j.anai.2026.01.014","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 614-615"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-evaluation of inhaled triple therapy data: Clinical insights and methodologic considerations","authors":"Tsai Ling Ting MSc ,&nbsp;Shiuan-Chih Chen MDPhD","doi":"10.1016/j.anai.2026.01.012","DOIUrl":"10.1016/j.anai.2026.01.012","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 613-614"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Undetectable IgE association with noninfectious complications of common variable immune deficiency","authors":"Susanna J. D’Silva BA ,&nbsp;James Patrie MS ,&nbsp;Emily Noonan BS ,&nbsp;Monica G. Lawrence MD ,&nbsp;Larry Borish MD","doi":"10.1016/j.anai.2025.12.003","DOIUrl":"10.1016/j.anai.2025.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Undetectable IgE levels are a frequent feature of common variable immunodeficiency (CVID). However, not much is known regarding the role of IgE levels as a prognostic factor in patients with CVID.</div></div><div><h3>Objective</h3><div>To evaluate whether undetectable IgE levels would be associated with higher risk of noninfectious complications of CVID.</div></div><div><h3>Methods</h3><div>We compared clinical and laboratory outcomes in 60 patients with CVID with detectable IgE and 89 patients with CVID with undetectable IgE.</div></div><div><h3>Results</h3><div>Undetectable IgE was associated with significantly lower IgG, IgM, and IgA concentrations. In addition, these patients had significantly lower numbers of CD4+ T cells, total B cells, plasmablasts, and reduced memory and especially switch memory B cells, but no difference in CD21low B cells. Undetectable IgE was associated with a significantly higher frequency of autoimmune cytopenias and lymphoma and trends toward higher relative frequencies of serious bacterial infections and granulomatous disease.</div></div><div><h3>Conclusion</h3><div>Undetectable IgE is a readily available biomarker that in a patient with CVID may direct clinicians to be particularly vigilant for noninfectious complications of CVID.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"136 5","pages":"Pages 572-577.e1"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}